Paragon Care Ltd Net Assets
Paragon Care Ltd net assets. Based on the latest financial reports, Paragon Care Ltd (PGC) has net assets worth AU$304.50 Million AUD (≈ $215.45 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.31 Billion ≈ $923.81 Million USD) and total liabilities (AU$1.00 Billion ≈ $708.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore PGC net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$304.50 Million |
| % of Total Assets | 23.32% |
| Annual Growth Rate | 16.25% |
| 5-Year Change | 162.52% |
| 10-Year Change | 338.37% |
| Growth Volatility | 127.33 |
Net Assets of Paragon Care Ltd (1999–2025)
Net assets of Paragon Care Ltd from 1999 to 2025. This chart illustrates how Paragon Care Ltd's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Paragon Care Ltd to measure how much of total assets are equity-financed.
Annual Net Assets for Paragon Care Ltd (1999–2025)
The table below shows the annual net assets of Paragon Care Ltd from 1999 to 2025. For live market cap and overall valuation, see Paragon Care Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$319.00 Million ≈ $225.72 Million |
+9.28% |
| 2024-06-30 | AU$291.92 Million ≈ $206.55 Million |
+15.86% |
| 2023-06-30 | AU$251.96 Million ≈ $178.28 Million |
+4.06% |
| 2022-06-30 | AU$242.12 Million ≈ $171.32 Million |
+99.25% |
| 2021-06-30 | AU$121.52 Million ≈ $85.98 Million |
+8.23% |
| 2020-06-30 | AU$112.28 Million ≈ $79.45 Million |
-41.62% |
| 2019-06-30 | AU$192.32 Million ≈ $136.08 Million |
+13.03% |
| 2018-06-30 | AU$170.14 Million ≈ $120.39 Million |
+105.76% |
| 2017-06-30 | AU$82.69 Million ≈ $58.51 Million |
+13.63% |
| 2016-06-30 | AU$72.77 Million ≈ $51.49 Million |
+253.54% |
| 2015-06-30 | AU$20.58 Million ≈ $14.56 Million |
+13.05% |
| 2014-06-30 | AU$18.21 Million ≈ $12.88 Million |
+75.59% |
| 2013-06-30 | AU$10.37 Million ≈ $7.34 Million |
+60.87% |
| 2012-06-30 | AU$6.45 Million ≈ $4.56 Million |
+27.52% |
| 2011-06-30 | AU$5.05 Million ≈ $3.58 Million |
+50.95% |
| 2010-06-30 | AU$3.35 Million ≈ $2.37 Million |
+7.91% |
| 2009-06-30 | AU$3.10 Million ≈ $2.20 Million |
+454.31% |
| 2008-06-30 | AU$559.85K ≈ $396.13K |
-52.67% |
| 2007-06-30 | AU$1.18 Million ≈ $836.97K |
-43.13% |
| 2006-06-30 | AU$2.08 Million ≈ $1.47 Million |
+7.00% |
| 2005-06-30 | AU$1.94 Million ≈ $1.38 Million |
+235.19% |
| 2004-06-30 | AU$579.94K ≈ $410.35K |
+357.50% |
| 2003-06-30 | AU$126.76K ≈ $89.69K |
-94.15% |
| 2002-06-30 | AU$2.17 Million ≈ $1.53 Million |
-65.80% |
| 2001-06-30 | AU$6.34 Million ≈ $4.48 Million |
+48.63% |
| 2000-06-30 | AU$4.26 Million ≈ $3.02 Million |
-33.04% |
| 1999-06-30 | AU$6.37 Million ≈ $4.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Paragon Care Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1587200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Paragon Care Ltd Net Assets Breakdown (June 2025)
Paragon Care Ltd net assets breakdown by equity component as of June 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$328.49 Million | 102.97% |
| Other Comprehensive Income | AU$6.39 Million | 2.00% |
| Total Equity | AU$319.00 Million | 100.00% |
Paragon Care Ltd Competitors by Market Cap
The table below lists competitors of Paragon Care Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Golden Ventures Leasehold Real Estate Investment Trust
BK:GVREIT
|
$181.59 Million |
|
Goldshore Resources Inc
V:GSHR
|
$181.61 Million |
|
Galan Lithium Limited
F:9CH
|
$181.64 Million |
|
Namhae Chemical
KO:025860
|
$181.64 Million |
|
Atlantic Lithium Ltd
AU:A11
|
$181.48 Million |
|
Digital Asset Acquisition Corp.
NASDAQ:DAAQ
|
$181.30 Million |
|
Hathway Cable & Datacom Limited
NSE:HATHWAY
|
$181.28 Million |
|
CHINA KEPEI ED. DL-00001
F:9CK
|
$181.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Paragon Care Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 291,918,000 to 319,004,000, a change of 27,086,000 (9.3%).
- Net income of 20,574,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 6,713,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$20.57 Million | +6.45% |
| Other Comprehensive Income | AU$6.71 Million | +2.1% |
| Other Changes | AU$-201.00K | -0.06% |
| Total Change | AU$- | 9.28% |
Book Value vs Market Value Analysis
This analysis compares Paragon Care Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.81x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 15.86x to 0.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-06-30 | AU$0.01 | AU$0.16 | x |
| 2000-06-30 | AU$0.01 | AU$0.16 | x |
| 2001-06-30 | AU$0.00 | AU$0.16 | x |
| 2002-06-30 | AU$0.00 | AU$0.16 | x |
| 2003-06-30 | AU$0.00 | AU$0.16 | x |
| 2004-06-30 | AU$0.00 | AU$0.16 | x |
| 2005-06-30 | AU$0.00 | AU$0.16 | x |
| 2006-06-30 | AU$0.00 | AU$0.16 | x |
| 2007-06-30 | AU$0.00 | AU$0.16 | x |
| 2008-06-30 | AU$0.00 | AU$0.16 | x |
| 2009-06-30 | AU$0.00 | AU$0.16 | x |
| 2010-06-30 | AU$0.01 | AU$0.16 | x |
| 2011-06-30 | AU$0.01 | AU$0.16 | x |
| 2012-06-30 | AU$0.01 | AU$0.16 | x |
| 2013-06-30 | AU$0.02 | AU$0.16 | x |
| 2014-06-30 | AU$0.03 | AU$0.16 | x |
| 2015-06-30 | AU$0.03 | AU$0.16 | x |
| 2016-06-30 | AU$0.11 | AU$0.16 | x |
| 2017-06-30 | AU$0.13 | AU$0.16 | x |
| 2018-06-30 | AU$0.26 | AU$0.16 | x |
| 2019-06-30 | AU$0.29 | AU$0.16 | x |
| 2020-06-30 | AU$0.17 | AU$0.16 | x |
| 2021-06-30 | AU$0.19 | AU$0.16 | x |
| 2022-06-30 | AU$0.51 | AU$0.16 | x |
| 2023-06-30 | AU$0.03 | AU$0.16 | x |
| 2024-06-30 | AU$0.31 | AU$0.16 | x |
| 2025-06-30 | AU$0.19 | AU$0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Paragon Care Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.45%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.57%
- • Asset Turnover: 2.93x
- • Equity Multiplier: 3.87x
- Recent ROE (6.45%) is below the historical average (31.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -8.28% | 0.00% | 0.00x | 1.05x | AU$-1.17 Million |
| 2000 | -92.51% | -148.72% | 0.42x | 1.47x | AU$-4.37 Million |
| 2001 | 0.00% | 4.05% | 3.22x | 0.00x | AU$1.54 Million |
| 2002 | 615.77% | 23.72% | 3.11x | 8.34x | AU$6.87 Million |
| 2003 | 815.52% | 225.61% | 1.24x | 2.91x | AU$1.02 Million |
| 2005 | -84.65% | -659.33% | 0.10x | 1.24x | AU$-1.84 Million |
| 2006 | -67.39% | -200.50% | 0.26x | 1.29x | AU$-1.61 Million |
| 2007 | -106.31% | -338.90% | 0.25x | 1.23x | AU$-1.38 Million |
| 2008 | -329.78% | -1834.84% | 0.07x | 2.40x | AU$-1.90 Million |
| 2009 | -11.47% | -31.59% | 0.28x | 1.28x | AU$-666.16K |
| 2010 | 4.41% | 1.78% | 0.70x | 3.52x | AU$-187.08K |
| 2011 | 16.84% | 5.81% | 0.81x | 3.57x | AU$345.70K |
| 2012 | -1.20% | -0.49% | 0.95x | 2.56x | AU$-722.09K |
| 2013 | 7.13% | 4.33% | 0.93x | 1.77x | AU$-297.34K |
| 2014 | 5.96% | 5.59% | 0.72x | 1.48x | AU$-735.94K |
| 2015 | 10.22% | 6.53% | 0.79x | 1.97x | AU$44.80K |
| 2016 | 10.35% | 8.06% | 0.63x | 2.03x | AU$253.50K |
| 2017 | 12.30% | 8.68% | 0.71x | 2.01x | AU$1.91 Million |
| 2018 | 6.44% | 9.34% | 0.34x | 2.06x | AU$-6.06 Million |
| 2019 | 4.61% | 3.75% | 0.61x | 2.00x | AU$-10.37 Million |
| 2020 | -68.82% | -33.35% | 0.79x | 2.60x | AU$-88.50 Million |
| 2021 | 6.81% | 3.51% | 0.81x | 2.40x | AU$-3.87 Million |
| 2022 | 2.81% | 2.79% | 0.54x | 1.86x | AU$-16.95 Million |
| 2023 | 67.79% | 4.16% | 0.69x | 23.76x | AU$10.91 Million |
| 2024 | 2.87% | 0.28% | 2.63x | 3.87x | AU$-20.81 Million |
| 2025 | 6.45% | 0.57% | 2.93x | 3.87x | AU$-11.33 Million |
Industry Comparison
This section compares Paragon Care Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $387,959,667
- Average return on equity (ROE) among peers: -3.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Paragon Care Ltd (PGC) | AU$304.50 Million | -8.28% | 3.29x | $181.54 Million |
| Ebos Group Ltd (EBO) | $182.79 Million | 12.82% | 1.84x | $2.52 Billion |
| Mayne Pharma Group Ltd (MYX) | $370.28 Million | -25.34% | 1.74x | $155.79 Million |
| Sigma Healthcare Ltd (SIG) | $610.81 Million | 3.06% | 0.73x | $23.03 Billion |
About Paragon Care Ltd
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provi… Read more